Entyvio is a prescription medicine used in adults for the treatment of:

  • moderately to severely active ulcerative colitis
  • moderately to severely active Crohn’s disease

Entyvio (vedolizumab), an integrin receptor antagonist, is a humanized IgG1 monoclonal antibody produced in Chinese hamster ovary cells that binds to the human α4β7 integrin. Entyvio has an approximate molecular weight of 147 kilodaltons.

Entyvio Info

Entyvio can be administered by intravenous infusion. 

The recommended dosage of ENTYVIO in adults with ulcerative colitis or Crohn’s disease is 300 mg administered by intravenous infusion at zero, two, and six weeks and then every eight weeks thereafter.

Entyvio Side Effects

The most common side effects include: 

  •  common cold symptoms (runny or stuffy nose, sinus pain, sneezing, cough),
  •  headache,
  •  joint pain,
  •  nausea,
  •  fever,
  •  infections of the nose and throat,
  •  tiredness,
  •  fatigue,
  •  upper respiratory tract infection,
  •  bronchitis,
  •  flu symptoms,
  •  back pain,
  •  rash,
  •  itching,
  •  sinus infection,
  •  sore throat, and
  •  pain in your arms or legs


Patient Assistance Programs

There are several programs patients can sign up for that will assist in treatment costs:


To learn more about this treatment, browse the resources below.

Order Form

To download the order form for this treatment, click below.

Ready to get started?

Contact us to chat with one of our helpful scheduling specialists!